Elizabeth could sense that he was becoming caught up by what he was saying, she could hear the undertone of pride in his voice, and she was oddly reminded of her father.
“Roffe and Sons owns factories and holding companies in over a hundred countries. Every one of them reports to this office.” He paused, as though to make sure that she understood the point. “Old Samuel went into business with a horse and a test tube. It’s grown to sixty factories around the world, ten research centers and a network of thousands of salesmen and detail men and women.” They were the ones, Elizabeth knew, who called on the doctors and hospitals. “Last year, in the United States alone, they spent over fourteen billion dollars on drugs—and we have a healthy share of that market.”
And yet Roffe and Sons was in trouble with the banks. Something was wrong.
Rhys took Elizabeth on a tour of the company’s headquarters’ factory. In actuality, the Zurich division was a dozen factories, with seventy-five buildings on the sixty acres of ground. It was a world in microcosm, completely self-sustaining. They visited the manufacturing plants, the research departments, the toxicology laboratories, the storage plants. Rhys brought Elizabeth to a sound stage, where they made motion pictures for research and for their worldwide advertising and products divisions. “We use more film here,” Rhys told Elizabeth, “than the major Hollywood studios.”
They went through the molecular biology department, and the liquid center, where fifty giant stainless steel, glasslined tanks hung suspended from the ceiling, filled with liquids ready to be bottled. They saw the tablet-compression rooms, where powders were formed into tablets, sized, stamped with ROFFE AND SONS, packaged and labeled, without anyone ever touching them. Some of the drugs were ethical products, available only on prescription, others were proprietary items, sold over the counter.
Set apart from the other buildings were several small buildings. These were for the scientists: the analytical chemists, biochemists, organic chemists, parasitologists, pathologists.
“More than three hundred scientists work here,” Rhys told Elizabeth. “Most of them are Ph.D.’s.
Would you like to see our hundred-million-dollar room?”
Elizabeth nodded, intrigued.
It was in an isolated brick building, guarded by a uniformed policeman with a gun. Rhys showed his security pass, and he and Elizabeth were permitted to enter a long corridor with a steel door at the end of it. The guard used two keys to open the door, and Elizabeth and Rhys entered. The room contained no windows. It was lined from floor to ceiling with shelves filled with every variety of bottles, jars and tubes.
“Why do they call this the hundred-million-dollar room?” Elizabeth asked.
“Because that’s what it cost to furnish it. See all those compounds on the shelves? None of them have names, only numbers. They’re the ones that didn’t make it. They’re the failures.”
“But a hundred million—”
“For every new drug that works, there are about a thousand that end up in this room. Some drugs are worked on for as long as ten years, and then abandoned. A single drug can cost five or ten million dollars in research before we find out that it’s no good, or that someone else has beaten us to it. We don’t throw any of these things away because now and then one of our bright young men will back into a discovery that can make something in this room valuable.”
The amounts of money involved were awesome.
“Come on,” Rhys said. “I’ll show you the Loss Room.”
It was in another building, this one unguarded, containing, like the other rooms, only shelves filled with bottles and jars.
“We lose a fortune here too,” Rhys said. “But we plan it that way.”
“I don’t understand.”
Rhys walked over to a shelf and picked up a bottle. It was labeled “Botulism.” “Do you know how many cases of botulism there were in the United States last year? Twenty-five. But it costs us millions of dollars to keep this drug in stock.” He picked up another bottle at random. “This is an antidote for rabies. This room is full of drugs that are cures for rare diseases—snakebites, poisonous plants. We furnish them free to the armed forces and to hospitals, as a public service.”